-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dravet syndrome is a rare childhood syndrome that affects 1 in 15,700 babies born in the United States and is characterized by encephalopathy and epilepsy
.
It is difficult to diagnose because many symptoms are not obvious in the first year after the child is born
Children's Epilepsy Diagnostic Fund
- Have normal or near-normal cognitive and motor development before epileptic seizure
Neuroene Therapeutics recently announced that the FDA has granted the company's proprietary compound NT102 the orphan drug designation
.
NT102 was developed as a mitochondrial and neuroprotective substance for the treatment of neurological diseases, such as drug-resistant epilepsy
FDA NT102 has a wide range of seizure protection in a variety of preclinical animal models, especially for the epileptic seizures of Dravet syndrome (a rare childhood syndrome characterized by severe encephalopathy and epilepsy)Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// leave a message here